Have a feature idea you'd love to see implemented?
Let us know!
Price (delayed)
$71.05
Market cap
$11.29B
P/E Ratio
74.79
Dividend/share
$0.32
EPS
$0.95
Enterprise value
$11.5B
Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company's
Highlights
BIO-TECHNE's debt has decreased by 27% YoY and by 4.9% QoQ
The quick ratio has increased by 17% since the previous quarter and by 4.7% year-on-year
The net income has decreased by 39% YoY and by 10% from the previous quarter
TECH's EPS is down by 39% year-on-year and by 11% since the previous quarter
Key stats
What are the main financial stats of TECH
Market
Valuations
Earnings
Shares outstanding
158.89M
Market cap
$11.29B
Enterprise value
$11.5B
Price to earnings (P/E)
74.79
Price to book (P/B)
5.27
Price to sales (P/S)
9.61
EV/EBIT
59.89
EV/EBITDA
37.91
EV/Sales
9.82
Revenue
$1.17B
EBIT
$192.04M
EBITDA
$303.35M
Free cash flow
$245.03M
Per share
Balance sheet
Liquidity
EPS
$0.95
Free cash flow per share
$1.55
Book value per share
$13.48
Revenue per share
$7.39
TBVPS
$7.99
Total assets
$2.74B
Total liabilities
$597.37M
Debt
$398.92M
Equity
$2.14B
Working capital
$506.44M
Debt to equity
0.19
Current ratio
4.56
Quick ratio
2.89
Net debt/EBITDA
0.7
Margins
Efficiency
Dividend
EBITDA margin
25.9%
Gross margin
65.5%
Net margin
12.9%
Operating margin
16.3%
Return on assets
5.5%
Return on equity
7.4%
Return on invested capital
13.7%
Return on capital employed
7.4%
Return on sales
16.4%
Dividend yield
0.45%
DPS
$0.32
Payout ratio
33.7%
TECH stock price
How has the BIO-TECHNE stock price performed over time
Intraday
3.39%
1 week
-2.05%
1 month
0.98%
1 year
11.85%
YTD
-7.92%
QTD
-11.11%
Financial performance
How have BIO-TECHNE's revenue and profit performed over time
Revenue
$1.17B
Gross profit
$767.55M
Operating income
$190.81M
Net income
$150.71M
Gross margin
65.5%
Net margin
12.9%
BIO-TECHNE's net margin has decreased by 40% YoY and by 11% QoQ
The net income has decreased by 39% YoY and by 10% from the previous quarter
BIO-TECHNE's operating margin has decreased by 38% YoY and by 8% QoQ
The company's operating income fell by 36% YoY and by 8% QoQ
Growth
What is BIO-TECHNE's growth rate over time
Valuation
What is BIO-TECHNE stock price valuation
P/E
74.79
P/B
5.27
P/S
9.61
EV/EBIT
59.89
EV/EBITDA
37.91
EV/Sales
9.82
TECH's EPS is down by 39% year-on-year and by 11% since the previous quarter
TECH's P/E is 20% above its 5-year quarterly average of 62.2 and 15% above its last 4 quarters average of 65.3
The stock's price to book (P/B) is 30% less than its 5-year quarterly average of 7.5 and 9% less than its last 4 quarters average of 5.8
BIO-TECHNE's equity has increased by 7% YoY and by 3.4% from the previous quarter
The price to sales (P/S) is 26% lower than the 5-year quarterly average of 13.0 and 6% lower than the last 4 quarters average of 10.2
The revenue has grown by 2.4% YoY
Efficiency
How efficient is BIO-TECHNE business performance
BIO-TECHNE's return on equity has decreased by 42% YoY and by 12% QoQ
TECH's return on assets is down by 42% year-on-year and by 11% since the previous quarter
BIO-TECHNE's ROIC has decreased by 40% YoY and by 2.8% from the previous quarter
TECH's return on sales is down by 36% year-on-year and by 6% since the previous quarter
Dividends
What is TECH's dividend history
DPS
$0.32
Dividend yield
0.45%
Payout ratio
33.7%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did BIO-TECHNE financials performed over time
BIO-TECHNE's total liabilities has decreased by 21% YoY and by 6% QoQ
TECH's current ratio is up by 18% from the previous quarter
BIO-TECHNE's debt is 81% lower than its equity
TECH's debt to equity is down by 32% year-on-year and by 5% since the previous quarter
BIO-TECHNE's debt has decreased by 27% YoY and by 4.9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.